Life Chemicals has always beendedicated to advancing drug discovery with its cutting-edge products. Following this route, we are happy to introduce our proprietary Pathway-based Screening Libraries for high-throughput screening (HTS). Moving beyond traditional single-target approaches, our novel screening sets focus on critical signaling and metabolic pathways, providing a more comprehensive and effective strategy for discovering multitarget inhibitors and overcoming drug resistance.
Currently Available Pathway Libraries:
-
Apoptosis Signaling Pathway Screening Library: 26,800 drug-like compounds potentially targeting proteins of the apoptotic signaling pathway;
-
PI3K/Akt/mTOR Focused Library: 4,600 drug-like screening compounds selected by a ligand-based approach for anti-cancer drug discovery projects;
-
RAS/MAPK Signaling Pathway Focused Library: 1,700 drug-like screening compounds, as potential inhibitors of various molecular targets in the RAS/MAPK pathway, selected using a 2D Similarity Search.
Why Explore Pathway-based Screening?
-
Enhanced Therapeutic Efficiency: target multiple proteins within a pathway to minimize drug resistance and improve treatment outcomes:
-
Uncover Multitarget Inhibitors: discover inhibitors that impact entire signaling cascades, essential for treating complex diseases;
-
Improved Hit Rates: pathway-based strategies are more likely to yield successful hits in early-phase drug discovery, helping elucidate protein-ligand binding mechanisms.
Contact us at orders@lifechemicals.com to learn more about our innovative solutions available to accelerate your next breakthrough!